Discussions with leaders: *JNM* editor-in-chief Johannes Czernin continues a series of interviews with leaders in nuclear and molecular imaging and therapy with a conversation with Joanna Fowler. ***Page 1191***

Solid-state detector SPECT MPI: Slomka and colleagues summarize state-of-the-art solid-state SPECT myocardial perfusion imaging technology and clinical applications, including emerging techniques for flow estimation, new protocols, potential pitfalls, and data on diagnostic and prognostic validation. ***Page 1194***

Training requirements for theranostics: Graham and Buatti offer preliminary advice for planning in modifying current residency training programs and education for practicing physicians to meet the demands of rapidly evolving theranostic applications in oncology. ***Page 1205***

Vascular calcification: Strauss and colleagues provide an educational overview of the evolving relationship of vascular calcification to major acute coronary events. ***Page 1207***

^{99m}Tc-NM-01 SPECT/CT PD-L1 imaging: Xing and colleagues assess safety, radiation dosimetry, uptake, and imaging of a single-domain antibody against programmed cell death ligand-1 radiolabeled site-specifically with ^{99m}Tc for SPECT in patients with non–small cell lung cancer. ***Page 1213***

Simplified methods for ^{18}F-FDHT quantitation: Kramer and colleagues describe simplified methods for quantifying ^{18}F-FDHT uptake in patients with metastatic castration-resistant prostate cancer and explore the effects of tumor perfusion on uptake metrics. ***Page 1221***

Additional imaging recommendations in ^{18}F-FDG PET/CT: Alesawi and colleagues assess the frequency, determinants, and costs of recommendations for additional imaging in clinical ^{18}F-FDG PET/CT reports. ***Page 1228***

^{18}F-florbetapir PET/CT in AL amyloidosis: Ehman and colleagues use ^{18}F-florbetapir PET/CT to detail the distribution and frequency of immunoglobulin amyloid light-chain deposits in the various organs of individuals with systemic AL amyloidosis. ***Page 1234***

5-Fluorouracil and epigenetic modifiers in NETs: Jin and colleagues report on an in vitro study exploring the effects of 5-fluorouracil plus the DNA methyltransferase inhibitor decitabine or the histone deacetylase inhibitor tacedinaline on neuroendocrine tumor cells. ***Page 1240***

^{18}F-FES imaging of active ER mutants: Kumar and colleagues determine the effect of estrogen receptor-α gene mutations in tyrosine 537 amino acid residue within the ligand-binding domain on ^{18}F-FES binding and in vivo tumor uptake. ***Page 1247***

PET/MRI in biochemical failure: Metser and colleagues assess whether the addition of multiparametric pelvic and whole-body MRI data to ^{18}F-FCH or ^{68}Ga-PSMA PET/CT improves detection of local tumor recurrence or nodal/distant metastases after radical prostatectomy with biochemical failure. ***Page 1253***

Multivariate analysis of PRRT: Aalbersberg and colleagues detail clinical and treatment parameters associated with progression-free and overall survival in patients undergoing peptide receptor radionuclide therapy for neuroendocrine neoplasms. ***Page 1259***

^{111}In-pentetreotide vs. ^{68}Ga-DOTATATE: Hope and colleagues compare the results of somatostatin-receptor PET–based and ^{111}In-pentetreotide–based Krenning scores in selection of patients for peptide receptor radionuclide therapy. ***Page 1266***

PSMA uptake in salivary glands: Rupp and colleagues investigate whether the accumulation of prostate-specific membrane antigen–targeting radioligands in submandibular glands can be explained with PSMA expression levels using autoradiography and immunohistochemistry. ***Page 1270***

qPSMA semiautomatic software: Gafita and colleagues introduce and validate a semiautomatic software package for whole-body tumor burden assessment using ^{68}Ga-prostate-specific membrane antigen 11 PET/CT in patients with prostate cancer. ***Page 1277***

Al^{18}F-PSMA-BCH PET for prostate cancer: Liu and colleagues report on the development and preclinical evaluation of an Al^{18}F-labeled radiotracer for PET imaging in prostate cancer and present results in newly diagnosed patients. ***Page 1284***

MSLN-TTC and DDR inhibitors: Wickstroem and colleagues explore the effects of blocking the DNA damage response pathway to further sensitize cancer cells and inhibit DNA repair, thereby increasing the response to mesothelin targeted ^{227}Th conjugate α-therapy. ***Page 1293***

^{211}At in thyroid cancer: Watabe and colleagues present in vitro and preclinical studies targeted at enhancing ^{211}At solution uptake in differentiated thyroid cancer by the addition of ascorbic acid and discuss potential clinical benefits. ***Page 1301***

CIRPI and pathology of TCFA: Zaman and colleagues describe development and testing of the catheter-based Circumferential Intravascular Radioluminescence Photoacoustic Imaging system in detection and characterization of thin-cap fibroatheroma structure and biology in rabbit abdominal aorta. ***Page 1308***

Immune response monitoring with ^{64}Cu-αCD11b: Cao and colleagues report on this tracer for longitudinal assessment by small-animal PET/CT of local and systemic immune response involving mobilization of CD11b^{+} myeloid cells. ***Page 1317***

Mesangial cell molecular imaging: Qin and colleagues demonstrate receptor-mediated binding of tilmanocept to CD206 within the kidney and provide evidence of kinetic sensitivity of this binding to renal function. ***Page 1325***